Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

ECO 2021 May 10 - 13

Once-Weekly Semaglutide 2.4 mg Improved Metabolic Syndrome in Adults With Overweight or Obesity: Post-Hoc Analysis of the STEP 1 Trial

Carel W le Roux1; Melanie Davies2‚3; Juan P Frias4; Camilla Jensen5; Peter Nørkjær Laursen5; Ildiko Lingvay6; Sriram Machineni7; Anette Varbo5; John PH Wilding8; Leigh Perreault9;
1Diabetes Complications Research Centre, Conway Institute University College, Dublin, Ireland; 2Diabetes Research Centre, University of Leicester, Leicester, UK; 3NIHR Leicester Biomedical Research Centre, Leicester, UK; 4National Research Institute, Los Angeles, CA, USA; 5Novo Nordisk A/S, Søborg, Denmark; 6Departments of Internal Medicine/Endocrinology and Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA; 7Division of Endocrinology and Metabolism, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC, USA; 8Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK; 9University of Colorado Anschutz Medical Campus, Aurora, CO, USA.;